NRx Pharmaceuticals Unveils potential Treatment for Suicidal Thoughts and Depression

Dr. Jonathan Javitt joined Steve Darling from Proactive to discuss groundbreaking developments in the treatment of suicidal ideation and depression.

Javitt told Proactive in a video presentation that NRX is approaching the clinical trial enrollment goals for its partnered product NRX-101. In addition, NRX is opening new clinical initiatives in chronic pain, urinary tract infection, and NRX-100 for suicidal depression.

Read More – https://www.proactiveinvestors.com/companies/news/1033413/nrx-pharmaceuticals-founder-unveils-potential-treatment-for-suicidal-thoughts-and-depression-1033413.html

Also found in the following articles:

• Wall Street Journal
• Nasdaq.com
• Benzinga
• Barron’s